On January 8, 2026, Monte Rosa Therapeutics, Inc. announced a public offering of 11,125,000 shares at $24.00 each, plus 1,375,000 pre-funded warrants, expecting to raise about $281.6 million to advance its drug development and operations through 2029. The offering is set to close around January 12, 2026.